Absci said it sees a larger opportunity beyond AI-driven drug discovery, shifting focus toward disease biology through pathways and chemical imbalances. The mov

Absci said it sees a larger opportunity beyond AI-driven drug discovery, shifting focus toward disease biology through pathways and chemical imbalances. The move broadens its strategy beyond drug design, though the company has yet to provide full details.